S
Suresh S. Ramalingam
Researcher at Emory University
Publications - 571
Citations - 48808
Suresh S. Ramalingam is an academic researcher from Emory University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 75, co-authored 502 publications receiving 34019 citations. Previous affiliations of Suresh S. Ramalingam include Boston Medical Center & University of Pittsburgh.
Papers
More filters
Journal ArticleDOI
Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network
Eric A. Collisson,Joshua D. Campbell,Angela N. Brooks,Angela N. Brooks,Alice H. Berger,William Lee,Juliann Chmielecki,David G. Beer,Leslie Cope,Chad J. Creighton,Ludmila Danilova,Li Ding,Gad Getz,Gad Getz,Peter S. Hammerman,D. Neil Hayes,Bryan Hernandez,James G. Herman,John V. Heymach,Igor Jurisica,Raju Kucherlapati,David J. Kwiatkowski,Marc Ladanyi,Gordon Robertson,Nikolaus Schultz,Ronglai Shen,Rileen Sinha,Carrie Sougnez,Ming-Sound Tsao,William D. Travis,John N. Weinstein,Dennis A. Wigle,Matthew D. Wilkerson,Andy Chu,Andrew D. Cherniack,Angela Hadjipanayis,Mara Rosenberg,Daniel J. Weisenberger,Peter W. Laird,Amie Radenbaugh,Singer Ma,Joshua M. Stuart,Lauren Averett Byers,Stephen B. Baylin,Ramaswamy Govindan,Matthew Meyerson,Matthew Meyerson,Stacey Gabriel,Kristian Cibulskis,Jaegil Kim,Chip Stewart,Lee Lichtenstein,Eric S. Lander,Eric S. Lander,Michael S. Lawrence,E. Getz,E. Getz,Robert S. Fulton,Lucinda Fulton,Michael D. McLellan,Richard K. Wilson,Kai Ye,Catrina Fronick,Christopher G. Maher,Christopher A. Miller,Michael C. Wendl,Christopher R. Cabanski,Elaine R. Mardis,David A. Wheeler,Miruna Balasundaram,Yaron S.N. Butterfield,Rebecca Carlsen,Eric Chuah,Noreen Dhalla,Ranabir Guin,Carrie Hirst,Darlene Lee,Haiyan I. Li,Michael Mayo,Richard A. Moore,Andrew J. Mungall,Jacqueline E. Schein,Payal Sipahimalani,Angela Tam,Richard Varhol,A. Gordon Robertson,Natasja Wye,Nina Thiessen,Robert A. Holt,Steven J.M. Jones,Marco A. Marra,Marcin Imielinski,Marcin Imielinski,Robert C. Onofrio,Eran Hodis,Travis I. Zack,Elena Helman,Chandra Sekhar Pedamallu,Jill P. Mesirov,Gordon Saksena,Steven E. Schumacher,Scott L. Carter,Levi A. Garraway,Levi A. Garraway,Rameen Beroukhim,Rameen Beroukhim,Semin Lee,Harshad S. Mahadeshwar,Angeliki Pantazi,Angeliki Pantazi,Alexei Protopopov,Xiaojia Ren,Sahil Seth,Xingzhi Song,Jiabin Tang,Lixing Yang,Jianhua Zhang,Peng Chieh Chen,Michael Parfenov,Andrew Wei Xu,Netty Santoso,Lynda Chin,Peter J. Park,Katherine A. Hoadley,J. Todd Auman,Shaowu Meng,Yan Shi,Elizabeth Buda,Scot Waring,Umadevi Veluvolu,Donghui Tan,Piotr A. Mieczkowski,Corbin D. Jones,Janae V. Simons,Matthew G. Soloway,Tom Bodenheimer,Stuart R. Jefferys,Jeffrey Roach,Alan P. Hoyle,Junyuan Wu,Saianand Balu,Darshan Singh,Jan F. Prins,James Stephen Marron,Joel S. Parker,Charles M. Perou,Jinze Liu,Dennis T. Maglinte,Philip H. Lai,Moiz S. Bootwalla,David Van Den Berg,Timothy J. Triche,Juok Cho,Daniel DiCara,David I. Heiman,Pei Lin,William Mallard,Douglas Voet,Hailei Zhang,Lihua Zou,Michael S. Noble,Nils Gehlenborg,Helga Thorvaldsdottir,Marc Danie Nazaire,James T. Robinson,B. Arman Aksoy,Giovanni Ciriello,Barry S. Taylor,Gideon Dresdner,Jianjiong Gao,Benjamin Gross,Venkatraman E. Seshan,Boris Reva,S. Onur Sumer,Nils Weinhold,Chris Sander,Sam Ng,Jingchun Zhu,Christopher C. Benz,Christina Yau,David Haussler,Paul T. Spellman,Patrick K. Kimes,Bradley M. Broom,Jing Wang,Yiling Lu,Patrick Kwok Shing Ng,Lixia Diao,Wenbin Liu,Christopher I. Amos,Rehan Akbani,Gordon B. Mills,Erin Curley,Joseph Paulauskis,Kevin Lau,Scott Morris,Troy Shelton,David Mallery,Johanna Gardner,Robert Penny,Charles Saller,Katherine Tarvin,William G. Richards,Robert J. Cerfolio,Ayesha S. Bryant,Daniel P. Raymond,Nathan A. Pennell,Carol Farver,Christine Czerwinski,Lori Huelsenbeck-Dill,Mary Iacocca,Nicholas J. Petrelli,Brenda Rabeno,Jennifer Brown,Thomas L. Bauer,Cureline Oleg Dolzhanskiy,Olga Potapova,D L Rotin,Olga Voronina,Elena Nemirovich-Danchenko,Konstantin V. Fedosenko,Anthony A. Gal,Madhusmita Behera,Suresh S. Ramalingam,Gabriel Sica,Douglas B. Flieder,Jeff Boyd,Jo Ellen Weaver,Bernard Kohl,Dang Huy Quoc Thinh,George E. Sandusky,Hartmut Juhl,Edwina Duhig,Peter B. Illei,Edward Gabrielson,James Shin,Beverly Lee,Kristen Rogers,Dante Trusty,Malcolm V. Brock,Christina Williamson,Eric J. Burks,Kimberly M. Rieger-Christ,Antonia H. Holway,Travis Sullivan,Michael K. Asiedu,Farhad Kosari,Natasha Rekhtman,Maureen F. Zakowski,Valerie W. Rusch,Paul Zippile,James Suh,Harvey I. Pass,Chandra Goparaju,Yvonne Owusu-Sarpong,John M. S. Bartlett,Sugy Kodeeswaran,Jeremy Parfitt,Harmanjatinder S. Sekhon,Monique Albert,John Eckman,Jerome Myers,Carl Morrison,Carmelo Gaudioso,Jeffrey A. Borgia,Philip Bonomi,Mark Pool,Michael J. Liptay,Fedor Moiseenko,Irina Zaytseva,Hendrik Dienemann,Michael Meister,Philipp A. Schnabel,Thomas Muley,Martin Peifer,Carmen Gomez-Fernandez,Lynn M. Herbert,Sophie C. Egea,Mei Huang,Leigh B. Thorne,Lori Boice,Ashley H. Salazar,William K. Funkhouser,W. Kimryn Rathmell,Rajiv Dhir,Samuel A. Yousem,Sanja Dacic,Frank Schneider,Jill M. Siegfried,Richard A. Hajek,Mark A. Watson,Sandra McDonald,Bryan F. Meyers,Belinda E. Clarke,Ian A. Yang,Kwun M. Fong,Lindy Hunter,Morgan Windsor,Rayleen V. Bowman,Solange Peters,Igor Letovanec,Khurram Z. Khan,Mark A. Jensen,Eric E. Snyder,Deepak Srinivasan,Ari B. Kahn,Julien Baboud,David Pot,Kenna R. Mills Shaw,Margi Sheth,Tanja Davidsen,John A. Demchok,Liming Yang,Zhining Wang,Roy Tarnuzzer,Jean C. Zenklusen,Bradley A. Ozenberger,Heidi J. Sofia,Richard T. Cheney +318 more
TL;DR: In this paper, the authors report molecular profiling of 230 resected lung adnocarcinomas using messenger RNA, microRNA and DNA sequencing integrated with copy number, methylation and proteomic analyses.
Journal ArticleDOI
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
Jean-Charles Soria,Yuichiro Ohe,Johan Vansteenkiste,Thanyanan Reungwetwattana,Busyamas Chewaskulyong,Ki Hyeong Lee,Arunee Dechaphunkul,Fumio Imamura,Naoyuki Nogami,Takayasu Kurata,Isamu Okamoto,Caicun Zhou,Byoung Chul Cho,Ying Cheng,Eun Kyung Cho,Pei Jye Voon,David Planchard,Wu Chou Su,Jhanelle E. Gray,Siow-Ming Lee,Rachel Hodge,Marcelo Marotti,Yuri Rukazenkov,Suresh S. Ramalingam +23 more
TL;DR: Osimertinib showed efficacy superior to that of standard EGFR‐TKIs in the first‐line treatment of EGFR mutation–positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events.
Journal ArticleDOI
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
Tony Mok,Yi-Long Wu,Myung-Ju Ahn,Marina Chiara Garassino,Hye Ryoun Kim,Suresh S. Ramalingam,Frances A. Shepherd,Yong He,Hiroaki Akamatsu,Willemijn S. M. E. Theelen,Chee Khoon Lee,Martin Sebastian,A. Templeton,Helen Mann,Marcelo Marotti,Serban Ghiorghiu,Vassiliki A. Papadimitrakopoulou +16 more
TL;DR: Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that is selective for both EGFR sensitizing and T790M resistance mutations in patients with non-small-cell lung cancer as mentioned in this paper.
Journal ArticleDOI
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
Matthew D. Hellmann,Tudor-Eliade Ciuleanu,Adam Pluzanski,Jong-Seok Lee,Gregory A. Otterson,Clarisse Audigier-Valette,Elisa Minenza,Helena Linardou,Sjaak Burgers,Pamela Salman,Hossein Borghaei,Suresh S. Ramalingam,Julie R. Brahmer,Martin Reck,Kenneth J. O'Byrne,William J. Geese,George Green,Han Chang,Joseph D. Szustakowski,Prabhu Bhagavatheeswaran,Diane Healey,Yali Fu,F. E. Nathan,Luis Paz-Ares +23 more
TL;DR: The benefit of nivolumab plus ipilimumab over chemotherapy was broadly consistent within subgroups, including patients with a PD‐L1 expression level of at least 1% and those with a level of less than 1%.
Journal ArticleDOI
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Pasi A. Jänne,James Chih-Hsin Yang,Dong Wan Kim,David Planchard,Yuichiro Ohe,Suresh S. Ramalingam,Myung-Ju Ahn,Sang We Kim,Wu Chou Su,Leora Horn,Daniel Haggstrom,Enriqueta Felip,Joo Hang Kim,Paul Frewer,Mireille Cantarini,Kathryn H. Brown,Paul A. Dickinson,Serban Ghiorghiu,Malcolm R Ranson +18 more
TL;DR: AZD9291 was highly active in patients with lung cancer with the EGFR T790M mutation who had had disease progression during prior therapy with EGFR tyrosine kinase inhibitors.